Monkeypox: From Emerging Trends to Therapeutic Concerns

被引:1
作者
Piparva, Kiran G. [1 ]
Fichadiya, Nilesh [2 ]
Joshi, Tejal [3 ]
Malek, Shahenaz [4 ]
机构
[1] All India Inst Med Sci AIIMS Rajkot, Dept Pharmacol, Rajkot, India
[2] Pandit Deendayal Upadhyay PDU Govt Med Coll, Dept Prevent & Social Med, Rajkot, India
[3] Pandit Deendayal Upadhyay PDU Govt Med Coll, Dept Microbiol, Rajkot, India
[4] Govt Med Coll, Dept Pharmacol, Surat, India
关键词
tecovirimat; vigiv; oxpv; pheic; hmxpv; mpox; bcv; MODIFIED VACCINIA ANKARA; SMALLPOX VACCINATION; UNITED-STATES; TRANSMISSION; OUTBREAK; SAFETY; VIRUS; MPOX;
D O I
10.7759/cureus.58866
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Monkeypox is a zoonotic viral disease. Monkeypox was first reported in humans about 54 years ago. Prior to the global outbreak, monkeypox was endemic to the rainforests of central and western African countries. In the last three years, increasing numbers of human monkeypox have been reported from various countries. Responding to the severity, monkeypox was declared a Public Health Emergency of International Concern by the World Health Organization. In the absence of approved drugs or clinical studies, repurposed drugs and therapeutic medical countermeasures effective against other orthopoxviruses have been utilized to treat severe human monkeypox cases. Currently, clinical trials are underway exploring the potential therapeutic effectiveness of tecovirimate in human monkeypox cases. Monoclonal antibodies, IFN-beta, resveratrol, and 15 triple-targeting FDA-approved drugs represent potential new drug targets for human monkeypox, necessitating further research.
引用
收藏
页数:11
相关论文
共 87 条
[41]  
cdc, 2020, Poxvirus
[42]   Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox [J].
Chan-Tack, Kirk M. ;
Harrington, Patrick R. ;
Choi, Su-Young ;
Myers, Laine ;
O'Rear, Julian ;
Seo, Shirley ;
McMillan, David ;
Ghantous, Hanan ;
Birnkrant, Debra ;
Sherwat, Adam, I .
LANCET INFECTIOUS DISEASES, 2019, 19 (06) :E221-E224
[43]   Short-term clinical safety profile of brincidofovir: A favorable benefit-risk proposition in the treatment of smallpox [J].
Chittick, Greg ;
Morrison, Marion ;
Brundage, Thomas ;
Nichols, W. Garrett .
ANTIVIRAL RESEARCH, 2017, 143 :269-277
[44]  
CHO CT, 1973, BACTERIOL REV, V37, P1
[45]   Status of human monkeypox: clinical disease, epidemiology and research [J].
Damon, Inger K. .
VACCINE, 2011, 29 :D54-D59
[46]   Human monkeypox: an emerging zoonosis [J].
Di Giulio, DB ;
Eckburg, PB .
LANCET INFECTIOUS DISEASES, 2004, 4 (01) :15-25
[47]   Assessing Monkeypox Virus Prevalence in Small Mammals at the Human-Animal Interface in the Democratic Republic of the Congo [J].
Doty, Jeffrey B. ;
Malekani, Jean M. ;
Kalemba, Lem's N. ;
Stanley, William T. ;
Monroe, Benjamin P. ;
Nakazawa, Yoshinori U. ;
Mauldin, Matthew R. ;
Bakambana, Tresor L. ;
Liyandja, Tobit Liyandja Dja ;
Braden, Zachary H. ;
Wallace, Ryan M. ;
Malekani, Divin V. ;
McCollum, Andrea M. ;
Gallardo-Romero, Nadia ;
Kondas, Ashley ;
Peterson, A. Townsend ;
Osorio, Jorge E. ;
Rocke, Tonie E. ;
Karem, Kevin L. ;
Emerson, Ginny L. ;
Carroll, Darin S. .
VIRUSES-BASEL, 2017, 9 (10)
[48]   Emergence of Monkeypox - West and Central Africa, 1970-2017 [J].
Durski, Kara N. ;
McCollum, Andrea M. ;
Nakazawa, Yoshinori ;
Petersen, Brett W. ;
Reynolds, Mary G. ;
Briand, Sylvie ;
Djingarey, Mamoudou Harouna ;
Olson, Victoria ;
Damon, Inger K. ;
Khalakdina, Asheena .
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2018, 67 (10) :306-310
[49]  
ema, 2021, Tecovirimat SIGA
[50]   THE TRANSMISSION POTENTIAL OF MONKEYPOX VIRUS IN HUMAN-POPULATIONS [J].
FINE, PEM ;
JEZEK, Z ;
GRAB, B ;
DIXON, H .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1988, 17 (03) :643-650